Overview

Effect of Acetazolamide on Cognition in Patients With Respiratory Disease at Altitude

Status:
Completed
Trial end date:
2017-07-24
Target enrollment:
0
Participant gender:
All
Summary
Randomized, placebo controlled trial evaluating the effect of acetazolamide on cognition in lowlanders with chronic obstructive pulmonary disease travelling from 760 m to 3200 m.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Zurich
Collaborator:
National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
Treatments:
Acetazolamide
Criteria
Inclusion Criteria:

- Male and female patients, age 18-75 yrs.

- COPD diagnosed according to GOLD, FEV1 40-80% predicted, SpO2 ≥92% at 750 m.

- Born, raised and currently living at low altitude (<800m).

- Written informed consent.

Exclusion Criteria:

- COPD exacerbation, very severe COPD with hypoxemia at low altitude (FEV1/FVC <0.7,
FEV1 <40% predicted, oxygen saturation on room air <92% at 750 m).

- Comorbidities such as uncontrolled cardiovascular disease, i.e., unstable systemic
arterial hypertension, coronary artery disease; previous stroke; OSA; pneumothorax in
the last 2 months.

- Internal, neurologic, rheumatologic or psychiatric disease including current heavy
smoking (>20 cigarettes per day)

- Known renal failure or allergy to acetazolamide and other sulfonamides